DNA methyltransferase and demethylase in human prostate cancer
Tóm tắt
Recent studies have shown that cytosine‐5 methylation at CpG islands in the regulatory sequence of a gene is one of the key mechanisms of inactivation. The enzymes responsible for CpG methylation are DNA methyltransferase (DNMT) 1, DNMT3a, and DNMT3b, and the enzyme responsible for demethylation is DNA demethylase (MBD2). Studies on methylation‐demethylation enzymes are lacking in human prostate cancer. We hypothesize that MBD2 enzyme activity is repressed and that DNMT1 enzyme activity is elevated in human prostate cancer. To test this hypothesis, we analyzed enzyme activities, mRNA, and protein levels of MBD2 and DNMT1, DNMT3a, and DNMT3b in human prostate cancer cell lines and tissues. The enzyme activities of DNMTs and MBD2 were analyzed by biochemical assay. The mRNA expression was analyzed by reverse transcriptase–polymerase chain reaction and by Northern blotting. The protein expression was measured by immunohistochemistry with specific antibodies. The results of these experiments demonstrated that (1) the activity of DNMTs was twofold to threefold higher in cancer cell lines and cancer tissues, as compared with a benign prostate epithelium cell line (BPH‐1) and benign prostatic hyperplasia (BPH) tissues; (2) MBD2 activity was lacking in prostate cancer cell lines but present in BPH‐1 cells; (3) immunohistochemical analyses exhibited higher expression of DNMT1 in all prostate cancer cell lines and cancer tissues, as compared with BPH‐1 cell lines and BPH tissues; (4) MBD2 protein expression was significantly higher in BPH‐1 cells and lacking in prostate cancer cell lines and, in BPH tissues, MBD2 protein expression was poorly observed, as compared with no expression in prostate cancer tissues; and (5) mRNA expression for DNMT1 was upregulated in prostate cancer, as compared with BPH‐1, and mRNA expression for MBD2 was found to be significantly expressed in all cases. The results of these studies clearly demonstrate that DNMT1 activity is upregulated, whereas MBD2 is repressed at the level of translation in human prostate cancer. These results may demonstrate molecular mechanisms of CpG hypermethylation of various genes in prostate cancer. © 2002 Wiley‐Liss, Inc.
Từ khóa
Tài liệu tham khảo
Bender CM, 1998, Inhibition of DNA methylation by 5‐AZA‐2′ deoxycytidine suppresses the growth of human tumor cell lines, Cancer Res, 58, 95
Erickson LC, 1991, The role of O‐6 methylguanine DNA methyltransferase (MGMT) in drug resistance and strategies for its inhibition, Semin Cancer Biol, 2, 257
Ahuja N, 1998, Aging and DNA methylation in colorectal mucosa and cancer, Cancer Res, 58, 5489
Li L‐C, 2000, Frequent methylation of estrogen receptor in prostate cancer: Correlation with tumor progression, Cancer Res, 60, 702
Kinosita H, 2000, Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer, Cancer Res, 60, 3623
Jarrard DF, 1998, Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells, Cancer Res, 58, 5310
Usmani BA, 2000, Methylation of the neutral endopeptidase gene promoter in human prostate cancer, Clin Cancer Res, 6, 1664
Herman JG, 1996, Hypermethylation‐associated inactivation indicates a tumor suppressor role for p15INK4B, Cancer Res, 56, 722
Graff JR, 1995, E‐cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas, Cancer Res, 55, 5195
Lou W, 1999, Methylation of the CD44 metastasis suppressor gene in human prostate cancer, Cancer Res, 59, 2329
Bedford MT, 1987, Hypomethylation of DNA in pathological conditions of the human prostate, Cancer Res, 47, 5274
Gjerset RA, 1982, Presence of a DNA demethylating activity in the nucleus of murine erythroleukemic cells, J Biol Chem, 257, 8581, 10.1016/S0021-9258(18)34161-9
Patra SK, 2001, DNA methyltransferase and histone deacetylase in prostate cancer Abstract, Proceedings of the American Association for Cancer Research, 42, 61
Butler TL, 2000, Hypomethylation of cytosine‐5 methyltransferase in human neoplasms, Anticancer Res, 20, 1435